Blue­Rock ex­pands Toron­to ops; Uni­ty brings B round to $151M; No­var­tis backs Al­tim­mune's $15M raise

⇨ Late last year Bay­er and Ver­sant Ven­tures turned some heads with a $225 mil­lion launch for a new stem cell play­er called Blue­Rock. To­day, the start­up an­nounced that it had re­cruit­ed in­dus­try vet Michael Scott as de­vel­op­ment chief as it cre­at­ed an R&D and man­u­fac­tur­ing site in Toron­to’s MaRS Dis­cov­ery Dis­trict. The biotech is col­lab­o­rat­ing with the Toron­to-based McEwen Cen­tre for Re­gen­er­a­tive Med­i­cine at Uni­ver­si­ty Health Net­work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.